Search

Your search keyword '"Overkamp, Friedrich"' showing total 321 results

Search Constraints

Start Over You searched for: Author "Overkamp, Friedrich" Remove constraint Author: "Overkamp, Friedrich"
321 results on '"Overkamp, Friedrich"'

Search Results

2. Return of individual genomic research results within the PRAEGNANT multicenter registry study

4. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany

5. Diagnostik und Therapie von Tumoren mit NTRK-Genfusionen

6. Klinische Endpunkte in Real-World-Register-Studien: PRAEGNANT-Netzwerk für Patientinnen mit fortgeschrittenem Mammakarzinom

9. Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors – Data from the German PRAEGNANT breast cancer registry

10. Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry

11. Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis

12. Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany

13. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

14. Hirntumoren

16. Use of complementary and integrative medicine among German breast cancer patients: predictors and implications for patient care within the PRAEGNANT study network

17. Return of individual genomic research results within the PRAEGNANT multicenter registry study

18. Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

19. Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients

20. Survival after secondary liver resection in metastatic colorectal cancer : Comparing data of three prospective randomized European trials ( LICC , CELIM , FIRE ‐3)

21. Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials ( LICC , CELIM , FIRE ‐3)

22. Update Mammakarzinom 2020 Teil 5 – Einführung von Substanzen aus der metastasierten Therapiesituation in die frühe Therapiesituation

23. Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status

25. Patientsʼ preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

26. Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer —Association With Patient and Disease Characteristics and Effect on Prognosis

27. Update Breast Cancer 2020 Part 5 – Moving Therapies From Advanced to Early Breast Cancer Patients

28. Update Mammakarzinom 2020 Teil 3 – frühes Mammakarzinom

29. Update Mammakarzinom 2020 Teil 4 – fortgeschrittenes Mammakarzinom

30. Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab

31. Additional file 1 of Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany

32. Additional file 2 of Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany

33. Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany

34. Corrigendum to “Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany”

35. Challenges and Opportunities for Real-World Evidence in Metastatic Luminal Breast Cancer

39. Vorwort

40. Everolimus in Metastatic Renal Cell Carcinoma after Failure of Initial Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor (VEGFr-TKI) Therapy: Results of an Interim Analysis of a Non-Interventional Study

42. Vorwort

43. Vorwort

44. Diagnosis and therapy of tumors with NTRK gene fusion

45. Correction: Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine

46. Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine

47. Update Breast Cancer 2020 Part 4 – Advanced Breast Cancer

48. Update Breast Cancer 2020 Part 3 – Early Breast Cancer

49. Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab

50. Update Mammakarzinom 2020 Teil 2 – fortgeschrittenes Mammakarzinom: neue Substanzen und Einzug diagnostikabhängiger Therapien

Catalog

Books, media, physical & digital resources